Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA
View
Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)
Indication:
Breast Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA
View
Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA
View
Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)
Indication:
Breast Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 Gem Carbo BC Preserve 2
View
Description: A Phase 3 Randomized Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2) (G1T28-208)
Indication:
Breast Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 Gem Carbo BC Preserve 2
View
Description: A Phase 3 Randomized Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2) (G1T28-208)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 Gem Carbo BC Preserve 2
View
Description: A Phase 3 Randomized Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2) (G1T28-208)
Indication:
Breast Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR Ph3 MRTX849 Cetux KRAS G12C CC
View
Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)
Indication:
Colon Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR Ph3 MRTX849 Cetux KRAS G12C CC
View
Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)
Indication:
Colon Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Ph3 MRTX849 Cetux KRAS G12C CC
View
Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)
Indication:
Colon Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
PH3 Ven+G vs FCR/BR in Fit untreated CLL
View
Description: A PROSPECTIVE OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION (CO41685)
Indication:
Leukemia
Location:
Texas Oncology-Harlingen
Phase: III
Title:
PH3 Ven+G vs FCR/BR in Fit untreated CLL
View
Description: A PROSPECTIVE OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION (CO41685)
Indication:
Leukemia
Location:
Texas Oncology-McAllen
Phase: III
Title:
PH3 Ven+G vs FCR/BR in Fit untreated CLL
View
Description: A PROSPECTIVE OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION (CO41685)
Indication:
Leukemia
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR PH3 EGFRm stage2/3b NSCLC
View
Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR PH3 EGFRm stage2/3b NSCLC
View
Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR PH3 EGFRm stage2/3b NSCLC
View
Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR PH3 JNJ-61186372 Peme EGFR NSCLC
View
Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)
Indication:
Lung Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR PH3 JNJ-61186372 Peme EGFR NSCLC
View
Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR PH3 JNJ-61186372 Peme EGFR NSCLC
View
Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)
Indication:
Lung Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR Ph3 Ami Laz EGFR-mut NSCLC
View
Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)
Indication:
Lung Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR Ph3 Ami Laz EGFR-mut NSCLC
View
Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Ph3 Ami Laz EGFR-mut NSCLC
View
Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)
Indication:
Lung Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
PH3 Sac Gov vs Doce NSCLC
View
Description: Open-label Global Multicenter Randomized Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) With Progression on or After Platinum-Based Chemotherapy and anti-PD-1/PD-L1 Immunotherapy (GS-US-577-6153)
Indication:
Lung Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
PH3 Sac Gov vs Doce NSCLC
View
Description: Open-label Global Multicenter Randomized Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) With Progression on or After Platinum-Based Chemotherapy and anti-PD-1/PD-L1 Immunotherapy (GS-US-577-6153)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
PH3 Sac Gov vs Doce NSCLC
View
Description: Open-label Global Multicenter Randomized Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) With Progression on or After Platinum-Based Chemotherapy and anti-PD-1/PD-L1 Immunotherapy (GS-US-577-6153)
Indication:
Lung Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 Tafa+ Lena R-CHOP B-Cell Lymp
View
Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Indication:
Lymphomas
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 Tafa+ Lena R-CHOP B-Cell Lymp
View
Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Indication:
Lymphomas
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 Tafa+ Lena R-CHOP B-Cell Lymp
View
Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Indication:
Lymphomas
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 LOXO-305 vs PC of BTK in MCL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)
Indication:
Lymphomas
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 LOXO-305 vs PC of BTK in MCL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)
Indication:
Lymphomas
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 LOXO-305 vs PC of BTK in MCL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)
Indication:
Lymphomas
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 LOXO-305 vs. InvChoice in CLL/SLL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)
Indication:
Lymphomas
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 LOXO-305 vs. InvChoice in CLL/SLL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)
Indication:
Lymphomas
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 LOXO-305 vs. InvChoice in CLL/SLL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)
Indication:
Lymphomas
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR Ph3 Navi Ruxo Myelofibrosis
View
Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)
Indication:
Myelofibrosis
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR Ph3 Navi Ruxo Myelofibrosis
View
Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)
Indication:
Myelofibrosis
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Ph3 Navi Ruxo Myelofibrosis
View
Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)
Indication:
Myelofibrosis
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC
View
Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC
View
Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC
View
Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Indication:
Prostate Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Indication:
Prostate Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Indication:
Prostate Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR PH3 Nirap Abira HRR mCSPC
View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR PH3 Nirap Abira HRR mCSPC
View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Indication:
Prostate Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR PH3 Nirap Abira HRR mCSPC
View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Weslaco
Phase: III